Keyphrases
Cisplatin
100%
Phase II Study
100%
Irinotecan
100%
Concurrent Radiotherapy
100%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
100%
Limited Disease
57%
Hematotoxicity
28%
Median Survival
28%
Survival Rate
28%
Diarrhea
14%
Chemotherapy
14%
Nave
14%
Radiotherapy
14%
Radiation Therapy
14%
Median Progression-free Survival
14%
Anemia
14%
Nonhematologic
14%
Partial Response
14%
Neutropenia
14%
Thrombocytopenia
14%
Once-daily
14%
Phase II Trial
14%
Extensive Disease
14%
Overall Survival Rate
14%
Response Rate
14%
Combination Therapy
14%
Progression-free Survival
14%
Etoposide
14%
2-year Survival
14%
Leukopenia
14%
Dysphagia
14%
Nausea-vomiting
14%
Randomized Phase III Trial
14%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Cisplatin
100%
Irinotecan
100%
Small Cell Lung Cancer
100%
Survival Rate
42%
Progression Free Survival
28%
Diarrhea
14%
Nausea
14%
Overall Survival
14%
Chemotherapy
14%
Anemia
14%
Thrombocytopenia
14%
Neutropenia
14%
Etoposide
14%
Phase II Trials
14%
Combination Therapy
14%
Dysphagia
14%
Leukopenia
14%